
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals is attractive because CARDAMYST already has U.S. approval as the first self-administered PSVT rescue therapy, addressing a clear treatment gap by helping patients avoid emergency care and giving the company a differentiated commercial platform. The recent NMPA approval in China further validates etripamil’s clinical and regulatory profile, triggers a $2M milestone payment, and leaves up to $98M of additional milestones plus royalties of up to 18% on Greater China sales, all without requiring Milestone to build local infrastructure. With commercial coverage now above 50%, roughly 800 prescribers, an estimated 3M-6M diagnosed PSVT patients in China, and optionality from the larger AFib-RVR program, the stock offers multiple levers for non-dilutive growth and long-term upside.
Bears say
Milestone Pharmaceuticals is viewed negatively because Cardamyst’s launch has been weaker than expected, with soft early prescription volume, limited prescriber productivity, and sales that have not validated the broad PSVT opportunity. The company’s investment case has shifted from regulatory uncertainty to commercial execution risk, yet prescriber breadth remains shallow, EPs may over-index, and cardiologist adoption is still constrained by WPW education and patient self-treatment concerns. With management expecting weighted-average net revenue per Rx to remain well below $500 for the rest of 2026, the company still faces operating losses, reliance on a single product, and possible dilution if the launch fails to generate sufficient cash flow.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares